Inga Jarosch

Dr. Inga Jarosch


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IJInga Jarosch
Inga Jarosch
TSTessa Schneeberger
Tessa Schneeberger
RGRainer Klinik Gloeckl
Rainer Klinik Gloeckl
MKMichael Kreuter
Michael Kreuter
MFMarion Frankenberger
Marion Frankenberger
KKKlaus Kenn
Klaus Kenn
The recommendation for pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) is weak with low-quality evidence. Therefore, the aim of this study is to investigate short-term PR effects and their maintenance after a 3-month follow-up. Fifty-four IPF patients were randomized into a group receiving a 3-week comprehensive, inpatient PR (n = 34, FVC: 74 ± 19% pred.) or usual care (UC) (n = 17, FVC: 72 ± 20%pred.). Outcomes were measured at baseline (T1), after intervention (T2), and 3 months after T2 (T3). A 6-min walk distance (6MWD) was used as the primary outcome and chronic respiratory disease questionnaire (CRQ) scores as the secondary outcome. Change in 6MWD from T1 to T2 (Δ = 61 m, 95% CI (18.5–102.4), p = 0.006) but not from T1 to T3 (∆ = 26 m, 95% CI (8.0–61.5), p = 0.16) differed significantly between groups. Higher baseline FVC and higher anxiety symptoms were significant predictors of better short-term 6MWD improvements. For the change in CRQ total score, a significant between-group difference from T1 to T2 (∆ = 3.0 pts, 95% CI (0.7–5.3), p = 0.01) and from T1 to T3 (∆ = 3.5 pts, 95% CI (1.5–5.4), p = 0.001) was found in favour of the PR group. To conclude, in addition to the short-term benefits, inpatient PR is effective at inducing medium-term quality of life improvements in IPF. PR in the early stages of the disease seems to provoke the best benefits.

21 May 2021 in Respiratory Medicine
Verified
Journal Article
Closed access
PDF file
VAVasileios Andrianopoulos
Vasileios Andrianopoulos
RGRainer Klinik Gloeckl
Rainer Klinik Gloeckl
TSTessa Schneeberger
Tessa Schneeberger
IJInga Jarosch
Inga Jarosch
IVIoannis Vogiatzis
Ioannis Vogiatzis
KKKlaus Kenn
Klaus Kenn

22 November 2023 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
TSTessa Schneeberger
Tessa Schneeberger
CDClancy John Dennis
Clancy John Dennis
IJInga Jarosch
Inga Jarosch
DLDaniela Leitl
Daniela Leitl
ASAntje Stegemann
Antje Stegemann
KKKlaus Kenn
Klaus Kenn
Background: People with very severe chronic obstructive pulmonary disease (COPD) using nocturnal non-invasive ventilation (NIV) for chronic hypercapnic respiratory failure (CHRF) experience reduced exercise capacity and severe dyspnoea during exercise training (ET). The use of NIV during ET can personalise training during pulmonary rehabilitation (PR) but whether high-intensity NIV (HI-NIV) during exercise is accepted and improves outcomes in these extremely physically limited patients is unknown. The aim of this trial was to determine if ET with HI-NIV during PR was more effective than without at improving exercise capacity and reducing dyspnoea during exercise. Methods: Patients with COPD, CHRF and nocturnal-NIV were randomised to supervised cycle-ET as part of PR with HI-NIV or without (control). Primary outcome was change in cycle endurance time (ΔCETtime), while secondary outcomes were dyspnoea at isotime during the cycle endurance test and during ET-sessions and for the HI-NIV group, post-trial preferred exercising method. Results: Twenty-six participants (forced expiratory volume in 1 s 22±7%pred, PaCO251±7 mm Hg) completed the trial (HI-NIV: n=13, ET: IPAP 26±3/EPAP 6±1 cm H2O; control n=13). At completion of a 3 week ET-programme, no significant between-group differences in ΔCETtime were seen (HI-NIV-control: Δ105 s 95% CI (−92 to 302), p=0.608). Within-group ΔCETtime was significant (HI-NIV: +246 s 95% CI (61 to 432); control: +141 s 95% CI (60 to 222); all pminimal important difference (MID)101 s: n=53.8%) was the same in both groups for absolute ΔCETtime and 69.2% of control and 76.9% of the HI-NIV group had a %change>MID33%. Compared with control, the HI-NIV group reported less isotime dyspnoea (Δ−2.0 pts. 95% CI (−3.2 to −0.8), p=0.005) and during ET (Δ−3.2 pts. 95% CI (−4.6 to −1.9), p<0.001). Most of the HI-NIV group (n=12/13) preferred exercising with NIV. Conclusion: In this small group of patients with very severe COPD requiring nocturnal NIV, participation in an ET-programme during PR significantly improved exercise capacity irrespective of HI-NIV use. Reported dyspnoea was in favour of HI-NIV. Trial registration number: NCT03803358.

19 August 2020 in Respiration
Verified
Journal Article
Closed access
PDF file
AKAndreas Rembert Koczulla
Andreas Rembert Koczulla
TBTobias Boeselt
Tobias Boeselt
JKJanina Koelpin
Janina Koelpin
FKFabian Kaufhold
Fabian Kaufhold
MVMartina Veith
Martina Veith
MKMichael Kreuter
Michael Kreuter
Background: Numerous studies have reported positive effects of exercise training in patients with interstitial lung disease (ILD) on physical capacity and quality of life. However, evidence is rare on the effects of specific forms of training and further pathophysiological mechanisms in these patients. Objectives: In this multicenter study we aimed to explore the clinical effects of whole-body vibration training (WBVT) in patients with ILD on various outcome measures, including proinflammatory cytokines and myostatin. Methods: We randomly assigned 26 patients with different forms of multidisciplinary confirmed fibrotic ILDs either to the WBVT group (n = 11; 55% male, 61 ± 14 years old, forced vital capacity 83.2 ± 29.3% predicted, 6-min walking distance [6MWD] 478 ± 79 m) performing 3 months of a standardized training (3 times per week), or to a control training group (CTG, n = 15; 60% male, 63 ± 9 years old, FVC 74.6 ± 20.5% predicted, 6MWD 455 ± 85 m) performing sham WBV training. Training in the two groups was performed on a GalileoTM vibration plate (6–20 vs. 5 Hz). The functional assessments before and after the intervention period included pulmonary function, 6MWD test, chair rise test, ultrasonographic measurement of quadriceps muscle thickness (cross-sectional area), quality of life questionnaires, and serum samples. Results: We observed a significant increase in 6MWD (∆Training = 30 m [12–67], p = 0.024) and a decrease of myostatin (∆Training = –465 pg/mL [–713 to –166], p = 0.008) in the WBVT group. In contrast, no significant differences were observed in the CTG. Conclusions: The present study demonstrates that WBVT is able to significantly increase 6MWD and decrease myostatin in patients with fibrotic ILDs. Therefore, WBVT seems to be a beneficial and feasible training modality in ILD patients. Clinical Trial Registry: German Clinical Trials Registry (DRKS00012930).

1 March 2024 in Respiration
Verified
Journal Article
Open access
PDF file
IJInga Jarosch
Inga Jarosch
TSTessa Schneeberger
Tessa Schneeberger
ASAntje Stegemann
Antje Stegemann
RGRainer Gloeckl
Rainer Gloeckl
DLDaniela Leitl
Daniela Leitl
AKAndreas Rembert Koczulla
Andreas Rembert Koczulla
Introduction: To objectify self-reported sleep disorders in individuals with post-COVID-syndrome (PCS), we aimed to investigate the prevalence and nature of sleep disturbances by polysomnography (PSG) in PCS compared to healthy individuals. Methods: People with PCS (n = 21) and healthy controls (CON, n = 10) were included in this prospective trial. At baseline, clinical and social anamnesis, lung function, 1 min sit-to-stand test (STST) and Pittsburgh Sleep Quality Index (PSQI) were assessed. For a single-night, sleep health was evaluated by video-PSG. The apnoea/hypopnea index (AHI) was used as the primary outcome. Results: Twenty patients with PCS (50 ± 11 y, BMI 27.1 m2/kg, SARS-CoV-2 infection 8.5 ± 4.5 months ago) and 10 CON participants (46 ± 10 y, BMI 23.0 m2/kg, no SARS-CoV-2 infection in the history) completed the study. Forced vital capacity (p = 0.018), STST repetitions (p < 0.001), and symptoms of dyspnoea (at rest: p = 0.002, exertion: p < 0.001) were worse in PCS compared to CON. PSQI score (PCS: 7.5 ± 4.7 points) was higher in PCS compared to CON (Δ = 3.7 points, 95% CI [0.4–7.1] p = 0.015), indicating poor sleep in 80% of patients with PCS. Although PSG showed comparable sleep stage distributions in both groups, AHI (Δ = 9.0 n/h, 95% CI [3.3–14.8], p = 0.002), PLM index (Δ = 5.1 n/h, 95% CI [0.4–9.8], p = 0.017), and the prevalence of sleep apnoea (60% vs. 10%, p = 0.028) was significantly higher in PCS compared to CON. Conclusion: Quantifiable subjective limitations of sleep have been revealed by PSG data in this PCS cohort. More than half of PCS patients had signs of sleep apnoea, highlighting the importance of sleep screening in PCS.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
RGRainer Klinik Gloeckl
Rainer Klinik Gloeckl
DLDaniela Leitl
Daniela Leitl
IJInga Jarosch
Inga Jarosch
TSTessa Schneeberger
Tessa Schneeberger
CNChristoph Nell
Christoph Nell
RKRembert A Koczulla
Rembert A Koczulla
Background: The new Corona-Virus disease (COVID-19) can result in a large variety of chronic health issues like impaired lung function, reduced exercise performance, and diminished quality of life. Our study aimed to investigate the efficacy, feasibility, and safety of pulmonary rehabilitation (PR) in COVID-19 patients and to compare outcomes between patients with a mild/moderate and a severe/critical course of the disease. Methods: Patients in the post-acute phase of a mild to critical course of COVID-19 admitted to a comprehensive three-week inpatient PR were included in this prospective, observational cohort study. Several measures of exercise performance (6-minute walk distance, 6MWD), lung function (forced vital capacity, FVC), and quality of life (36 question short-form health survey, SF-36) were assessed before and after PR. Results: Fifty patients were included in the study (24 with mild/moderate and 26 with severe/critical COVID-19). On admission, patients had a reduced 6MWD (mild/moderate: 509m; severe/critical: 344m), an impaired FVC (mild/moderate: 80%; severe/critical: 75%) and a low SF-36 mental health score (mild/moderate: 49pts; severe/critical: 39pts). Patients attended a median of 100% [94-100] of all provided PR sessions. At discharge, patients in both subgroups improved in 6MWD (mild/moderate: +48m [35-113m]; severe/critical: +124m [75-145m], both p<0.001), FVC (mild/moderate: +7.7%, p=0.002; severe/critical: +11.3%, p<0.001) and SF-36 mental component (mild/moderate +5.6pts, p=0.071; severe/critical: +14.4pts, p<0.001). No adverse event was observed. Conclusion: Our study shows that PR is a feasible, safe, and effective therapeutic option in COVID-19 patients.